Fungus (1-3)-beta-D-Glucan Detection Kit 110T

Product Description

~Fungus (**3)-β-D-Glucan Detection Kit **0T ( Applied on Microplate Reader )

Qualitative detection for fungus (**3)-β-D-Glucan in human serum.
**0 Tests
Chromogenic method
ITEM NO. : BGW*****1

Overview
The Fungus (**3)-β-D-Glucan Detection Kit is a highly sensitive and rapid diagnostic test that detects (**3)-β-D-Glucan qualitatively in human serum. The assay be used to provide rapid diagnosis reference for the clinicians in identifying Invasive Fungal Disease (IFD) early in the disease process.

Assay Characteristics
Basic Parameters 
Item No. BGW*****1
Sample type serum
Specification **0 tests/kit
Detection time *0min
Detection range *7.****0pg/m
Endotoxin shielding capability 1.0 EU/mL
Inter assay variation ≤*0%
Detection objects Candida, Aspergillus, Fusarium, Trichosporon, Pneumocystis carinii, Geotrichum, Histoplasmosis, Acremonium, Coccidioides immitis, Saccharomyces cerevisiae, etc.
(Cryptococcus and Zygomycetes are not included.)
Machine to operate on Microplate Reader with thermostat and dynamic function

Principle of the Test
The assay is a protease zymogen-based chromogenic assay for the qualitative detection of (**3)-β-D-Glucan in the serum of patients with symptoms of, or medical conditions predisposing  the patient to, invasive fungal infection. The serum concentration of (**3)-β-D-Glucan, a major  cell-wall component of various medically important fungi, can be used as an aid in the diagnosis  of Invasive Fungal Disease (IFD).
(**3)-β-D-Glucan can specifically activate Factor G in the main reagent, and the serine protease zymogen, etc. The activated Factor G converts the inactive pro-clotting enzyme to the active clotting enzyme, which in turn cleaves pNA from the chromogenic peptide substrate, Boc-Leu-Gly-Arg-pNA, creating a chromophore pNA that absorbs at **5 nm. There are additive ampholyte glycine, paromycin and surfactant in the reagent which can inhibit the activation of Factor B and Factor C. Therefore the kit has a specific shielding effect on Gram negative bacteria lipopolysaccharide.

Clinical Significance
The incidence of invasive fungal infection (IFI) by both primary and opportunistic pathogens,has been steadily increasing among hematological malignancy and AIDS patients and the patients receiving aggressive chemotherapy for cancer, bone marrow and organ transplantation or advanced critical care. The difficulty in diagnosis of these infections are associated with significant mortality and morbidity. Since the traditional methods for the fungal infection detection such as blood culture and histopathological diagnosis are either less sensitive or not feasible in the critically ill patients, development of untraditional method for the IFI diagnosis is of great importance.
Among the new diagnostic techniques is the assay for the serum (**3)-β-d -glucan (BG) detection. Positive in the BG test has been recognized as a very important microbiological evidence in the clinical diagnostic criteria for invasive fungal infection, which can achieve early diagnosis for IFI and dynamic monitoring among patients with risks of IFI. What is more, BG test results provide basis to the use of medicine and pharmacodynamics evaluation in clinical treatment.

Samples Collection and Storage
Collect venous blood samples 4ml with sterile non-pyrogenic vacuum tubes (red tops). The serum is then separated from the blood by centrifuge (***0 rmp/min for ****5 minutes) and transferred to a suitable container with no (**3)-β-D-Glucan. Detect within 2 hours.
Serum that is hemolyzed, lipemic, or visually icteric or turbid is not suitable for use with the assay.

Serum samples should be stored at **8℃or frozen at **0℃ or colder within *4 hours after collection. The serum samples should avoid repeated freezing and thawing.

Because a fungal infection is a dynamic process repeat testing, typically **3 times per week, improves sensitivity. 

Result Interpretation
Negative  /= *0 pg/mL